Related Experiment Video
Updated: Jun 13, 2026

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Impact of donor quality on outcome of heart transplantation
Alberto Forni1, Giovanni Battista Luciani, Bartolomeo Chiominto
1Division of Cardiac Surgery and Cardiology, University of Verona, OCM Piazzale Stefani 1, Verona 37126, Italy.
Insights
Utilizing marginal donors for heart transplantation, even in younger recipients, shows comparable outcomes to optimal donors. This suggests expanded donor criteria can be safely implemented, improving heart transplant accessibility.
Area of Science:
- Cardiology
- Transplantation Medicine
- Immunology
Background:
- Donor and recipient profiles in heart transplantation have evolved.
- Marginal donor utilization has shown promise in older recipients.
- This study investigates the impact of donor quality across different recipient age groups.
Purpose of the Study:
- To assess the impact of donor quality on heart transplantation outcomes.
- To evaluate the safety and efficacy of using marginal donors in younger recipients.
- To compare clinical outcomes between younger and older recipients receiving optimal or marginal grafts.
Main Methods:
- Retrospective review of 181 heart transplant recipients (2000-2009).
- Patients categorized into younger (18-60 years) and older (61-70 years) groups.
- Subgroups based on donor quality: optimal vs. marginal grafts.
Main Results:
- Overall 9-year survival was 78%.
- No statistically significant differences in graft failure, rejection, or organ dysfunction among groups.
- Older recipients of marginal donors showed a trend towards more pacemaker implants.
Conclusions:
- Extended donor acceptance criteria appear safe and do not compromise clinical outcomes in heart transplantation.
- Marginal donor utilization can be considered for a broader range of recipients.
- Further long-term follow-up is recommended to validate these findings.
Objective:
Over the last few years, there have been changes in both donor and recipient profiles in heart transplantation. Encouraging clinical outcome of marginal donors in candidates older than 60 years of age led us to allocate suboptimal donors for younger recipients as well. We reviewed our experience retrospectively so as to assess the impact of donor quality on heart transplantation.
Methods:
Among 181 patients who underwent heart transplantation between January 2000 and February 2009, there were 75 patients (41%) aged 61-70 years and 106 patients (59%) ranging in age between 18 and 60 years. According to the recipient's age, they were classified into four groups. The younger recipients (106 patients) had either optimal donors (70 patients, group 1) or marginal donors (36 patients, group 2). The older recipients (75 patients) had either marginal grafts (64 patients, group 3) or optimal grafts (11 patients, group 4). Sex distribution, cause of end-stage heart failure, preoperative pulmonary hypertension, pre-heart-transplantation clinical status or mean follow-up duration did not show any statistically significant difference among the four groups.
Results:
Overall, the 9-year actuarial survival rate was 78%±1%. The 30 days and 9-year actuarial survival rates were 94%±2% and 80%±1% in group 1; 86%±5% and 55%±12% in group 2; 90%±4% and 73%±7% in group 3; 99%±1% and 82%±7% in group 4 (P=0.07). Comparison among the four groups did not show any statistical difference in terms of freedom from graft failure (P=0.3), right ventricular failure (P=0.3), acute rejection (P=0.2), chronic rejection (P=0.2), neoplasia (P=0.5) and chronic renal failure (P=0.2). Older recipients of marginal donors (group 3) had slightly higher prevalence of permanent pacemaker implants: eight permanent pacemakers versus two in group 2, and none in group 1 and group 4 (P=0.4).
Conclusions:
Our results suggest that extended donor acceptance criteria may not compromise clinical outcome after heart transplantation. Further follow-up is warranted.
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

